Letter to the Editor Regarding "Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children Under Five Years of Age"

Infect Dis Ther. 2023 Jan;12(1):291-294. doi: 10.1007/s40121-022-00718-5. Epub 2022 Nov 14.

¹ Global Medical and Scientific Affairs, Merck & Co., Inc., Rahway, NJ, USA.
² Center for Observational and Real-World Evidence, Merck & Co., Inc., 351 N Sumneytown Pike, North Wales, PA, 19454, USA. thomas_weiss@merck.com.

No abstract available

Keywords: Children; Decision-analytic model; Pneumococcal conjugate vaccines; Pneumococcal disease; Pneumococcal serotypes.

Publication types